Teva drops attempts to void Angiomax patents, but will supply |Medicines with the active ingredient

Israel’s Teva Pharmaceuticals has come to an agreement with the Medicines Company to settle their invalidation attempt against the Angiomax patents.

Under the agreement, Teva acknowledges the validity of the Angiomax patents and will only begin selling a generic version of the anti-clotting drug in 2019. However, Teva will supply Medicines with bivalirudin, the active ingredient in Angiomax.

The agreement is subject to review by the Federal Trade Commission and the U.S. Department of Justice.

For more details, see

Categories: drugs, Israel, Patents, pharmaceuticals, pharmaceuticals and Biotechnology

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: